AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
dexrabeprazole 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antiulcer, benzimidazole derivatives | 4867 | 177795-60-7 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
|
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,AKT2,AKT3,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,CHEK1,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GSK3B,IGF1R,ITK,JAK2,JAK3,MAP3K1,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPK8,MAPK9,MAPKAPK2,MARK4,MELK,MET,MTOR,NTRK2,PAK4,PDK1,PDK2,PDK4,PDPK1,PIK3CA,PIK3CB,PIK3CD,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TTK,ULK1,ZAP70 | 57 | |||
| kinase-selectivity-class | AXL,BRAF | 2 | |||
| mdck-mdr1-bcrp-efflux | MDCK-MDR1-BCRP efflux ratio | 3.936 | High | 1 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pld-class | Phospholipidosis risk class (1 = positive, 0 = negative) | 0 | High | 1 | |
| rat-kpuu-brain | Rat brain Kpuu | 0.139 | % | High | 1 |
Approvals:
None
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | A02BC07 | ALIMENTARY TRACT AND METABOLISM DRUGS FOR ACID RELATED DISORDERS DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) Proton pump inhibitors |
| MeSH PA | D000897 | Anti-Ulcer Agents |
| MeSH PA | D004791 | Enzyme Inhibitors |
| MeSH PA | D005765 | Gastrointestinal Agents |
| MeSH PA | D054328 | Proton Pump Inhibitors |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:63457 | fibroblast growth factor receptor antagonist |
| CHEBI has role | CHEBI:65207 | vascular endothelial growth factor receptor antagonist |
Related Drugs by ATC class:
A02BC Proton pump inhibitors 8 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Peptic ulcer | indication | 13200003 | DOID:750 |
| Erosive esophagitis | indication | 40719004 | |
| Duodenal ulcer disease | indication | 51868009 | DOID:1724 |
| Zollinger-Ellison syndrome | indication | 53132006 | DOID:0050782 |
| Peptic reflux disease | indication | 57643001 | |
| Gastroesophageal reflux disease | indication | 235595009 | DOID:8534 |
| Gastric ulcer | indication | 397825006 | DOID:10808 |
| Gastric Hypersecretory Conditions | indication | ||
| Maintenance of Healing Erosive Esophagitis | indication | ||
| Duodenal Ulcer due to H. Pylori | indication | ||
| Pathological Gastric Hypersecretory Condition | indication | ||
| Upper gastrointestinal hemorrhage | off-label use | 37372002 | |
| Chronic heart failure | contraindication | 48447003 | |
| Acute nephropathy | contraindication | 58574008 | |
| Hepatic failure | contraindication | 59927004 | |
| Osteoporosis | contraindication | 64859006 | DOID:11476 |
| Oliguria | contraindication | 83128009 | |
| Atrophic gastritis | contraindication | 84568007 | DOID:8929 |
| Fracture of bone | contraindication | 125605004 | |
| Hypomagnesemia | contraindication | 190855004 | |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Edema | contraindication | 267038008 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 9.23 | acidic |
| pKa2 | 3.9 | Basic |
| pKa3 | 2.72 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Potassium-transporting ATPase | Transporter | INHIBITOR | SCIENTIFIC LITERATURE | SCIENTIFIC LITERATURE | |||||
| D(3) dopamine receptor | GPCR | Ki | 6.10 | CHEMBL | |||||
| Adenosine receptor A3 | GPCR | Ki | 5.74 | CHEMBL | |||||
| ATP-binding cassette sub-family G member 2 | Transporter | IC50 | 5.07 | CHEMBL | |||||
| Platelet-derived growth factor receptor beta | Kinase | Kd | 6.56 | CHEMBL | |||||
| Pyridoxal kinase | Kinase | Kd | 4.79 | CHEMBL | |||||
| Proto-oncogene tyrosine-protein kinase receptor Ret | Kinase | Kd | 8.30 | CHEMBL | |||||
| Vascular endothelial growth factor receptor 1 | Kinase | IC50 | 8.15 | CHEMBL | |||||
| Vascular endothelial growth factor receptor 2 | Kinase | IC50 | 7.60 | CHEMBL | |||||
| Vascular endothelial growth factor receptor 3 | Kinase | IC50 | 8 | CHEMBL | |||||
| Fibroblast growth factor receptor 3 | Kinase | IC50 | 6.62 | CHEMBL | |||||
| Tyrosine-protein kinase Lyn | Kinase | Kd | 5.56 | CHEMBL | |||||
| Alpha-2B adrenergic receptor | GPCR | Ki | 6.10 | CHEMBL | |||||
| Fatty acid synthase | Enzyme | Ki | 5.23 | CHEMBL | |||||
| Fibroblast growth factor receptor 2 | Kinase | IC50 | 7.08 | CHEMBL | |||||
| Receptor-interacting serine/threonine-protein kinase 2 | Kinase | Kd | 6.70 | CHEMBL | |||||
| Epithelial discoidin domain-containing receptor 1 | Kinase | Kd | 7.85 | CHEMBL | |||||
| Discoidin domain-containing receptor 2 | Kinase | Kd | 7.03 | CHEMBL | |||||
| Aurora kinase B | Kinase | Kd | 4.64 | CHEMBL | |||||
| Insulin-degrading enzyme | Enzyme | IC50 | 4.96 | CHEMBL | |||||
| N(G),N(G)-dimethylarginine dimethylaminohydrolase 1 | Enzyme | IC50 | 4.28 | CHEMBL | |||||
| Cytosolic endo-beta-N-acetylglucosaminidase | Enzyme | IC50 | 5.35 | CHEMBL | |||||
| Sterile alpha and TIR motif-containing protein 1 | Enzyme | IC50 | 5.50 | CHEMBL | |||||
| Fibroblast growth factor receptor 1 | Kinase | IC50 | 7.76 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 65JK8810RM | UNII |
| 171440-18-9 | SECONDARY_CAS_RN |
| C3661450 | UMLSCUI |
| CHEMBL1615209 | ChEMBL_ID |
| 9906855 | PUBCHEM_CID |
| DB13762 | DRUGBANK_ID |
| CHEMBL2220486 | ChEMBL_ID |
| CHEMBL1219 | ChEMBL_ID |
| CHEMBL1200930 | ChEMBL_ID |
| D064750 | MESH_DESCRIPTOR_UI |
| C000595232 | MESH_SUPPLEMENTAL_RECORD_UI |
| 1177188006 | SNOMEDCT_US |
| 1179585005 | SNOMEDCT_US |
| CHEBI:134729 | CHEBI |
| RZX | PDB_CHEM_ID |
Pharmaceutical products:
None